Replies to post #748 on RespireRx Pharmaceuticals Inc (RSPI)

[midastouch017]

Aiming,

A phrase in general:

Where a beetle is found, it is bound to have some
relatives in hiding nearby.

A minor issue it may indeed be, however chances are
additional minor issues will pop up further down the
road.

I am not talking 'science', but from lifelong experience.

Regards,

Dubi

[gfp927z]

Aiming, I wouldn't assume that this is a minor problem. A clinical hold indicates that either - 1) there's a bonafide science problem that only revealed itself after 3 months of dosing, or 2) the FDA is trying to stonewall CX-717 for some non-science related reason. Either way it spells trouble. At the very least it likely means doing additional 3 month animal studies (perhaps a 9 month delay). At the worst, the platform is in trouble. If the FDA's concern is clearly BS, BP suitors might realize that, and a BP deal *might* happen despite the clinical hold, but the odds of that happening aren't something I would bet on.

The prudent approach would be to just give Cortex an equal weighting in a diversified portfolio (say 8-12 bio stocks). That's a sound strategy to have anyway, regardless of the merits of Cortex or any other bio stock. These stocks are just too unpredictable, and sooner or later a "bet the farm" approach will blow up in your face -- just look at what happened to PARS, CTIC, EPIX, GTCB - these stocks made fools out of of some smart/experienced investors, and Cortex could easily do the same. So proceed with caution, and live to fight another day.